Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
| Autor: | Takayuki Ishikawa, Satoshi Yoshioka, Madoka Kanda-Kato |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Poor prognosis medicine.medical_specialty Cyclophosphamide Case Report Disease Gastroenterology lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Cord blood transplantation Mycosis fungoides Hematopoietic cell business.industry Complete remission medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Transplantation 030104 developmental biology surgical procedures operative Oncology 030220 oncology & carcinogenesis Sézary syndrome Posttransplant cyclophosphamide business Haploidentical hematopoietic cell transplantation medicine.drug |
| Zdroj: | Case Reports in Oncology Case Reports in Oncology, Vol 13, Iss 2, Pp 1053-1058 (2020) |
| ISSN: | 1662-6575 |
| Popis: | Patients with advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) have a poor prognosis. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment option; however, since most patients with MF/SS are elderly, they often have difficulty in finding HLA-matched donors. In recent years, HCT from HLA-haploidentical donors (haplo-HCT) using posttransplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis has been conducted for patients without HLA-matched donors. Infectious complications, particularly cutaneous bacterial infections, are common among patients with MF/SS. The lower incidence of severe infectious complications after haplo-HCT than after an unrelated cord blood transplantation could lead to lower transplant-related mortality. Here, we report on a patient with SS who was treated successfully with haplo-HCT with PTCy. The patient has remained in complete remission for more than 24 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|